AN2 Therapeutics officer reports initial share holdings

AN2 Therapeutics’ Principal Accounting Officer, Sarah Joanne Williams, filed an initial statement of beneficial ownership as of January 26, 2026.

Rhea-AI Filing Summary

AN2 Therapeutics’ Principal Accounting Officer, Sarah Joanne Williams, filed an initial statement of beneficial ownership as of January 26, 2026. She directly holds 18,800 shares of common stock, which include remaining restricted stock units (RSUs) that vest over four-year schedules beginning May 28, 2024 and January 1, 2025.

Williams also holds stock options to purchase 21,875 shares at $1.13 per share, expiring on February 25, 2035, and options for 23,700 shares at $2.07 per share, expiring on June 16, 2034. These options vest gradually over four years, subject to her continued service with the company.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Williams Sarah Joanne

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 45,575 contracts (Direct); Common Stock — 18,800 shares (Direct)

Footnotes (3)

1. F1. Includes the balance of (a) 10,938 RSUs which vest as follows: 1/4th of the RSUs vest in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (b) 11,850 RSUs which vest as follows: 1/16th of the RSUs vest in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. A total of 3,174 shares from the aggregate number of the RSUs issued under (a) and (b) above were sold to cover taxes and a total of 814 shares were sold on the open market.
2. F2. The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and become exercisable (rounded down to the nearest whole number of shares) monthly over four years from January 1, 2025 until fully vested and exercisable on January 1, 2029, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
3. F3. The shares subject to the option are exercisable and vest as follows: 1/4th of the shares vest and become exercisable (rounded down to the nearest whole number of shares) on the first anniversary of May 28, 2024, and 1/48th of the shares vest and become exercisable monthly (rounded down to the nearest whole number of shares) over the following three years until fully vested and exercisable on May 28, 2028, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ANTX Form 3 filing by Sarah Joanne Williams report?

The Form 3 reports initial beneficial ownership for Sarah Joanne Williams at AN2 Therapeutics. It shows her directly holding 18,800 common shares plus stock options and RSUs that vest over several years, reflecting her equity-based compensation as Principal Accounting Officer.

How many AN2 Therapeutics (ANTX) common shares does Sarah Joanne Williams own?

Sarah Joanne Williams directly owns 18,800 shares of AN2 Therapeutics common stock. This figure includes remaining restricted stock units that vest over four-year schedules starting on May 28, 2024 and January 1, 2025, subject to continued service with the company.

What stock options are reported in the ANTX Form 3 for Sarah Joanne Williams?

The filing shows stock options for 21,875 common shares at $1.13 per share expiring February 25, 2035, and options for 23,700 shares at $2.07 per share expiring June 16, 2034, all held directly and vesting over four years.

How do Sarah Joanne Williams’ ANTX RSUs vest over time?

The filing describes 10,938 RSUs vesting annually over four years from January 1, 2025, and 11,850 RSUs vesting quarterly over four years from May 28, 2024. Vesting requires her continued service as employee, consultant, or director.

Were any AN2 Therapeutics RSU shares sold in connection with this Form 3?

The disclosure notes 3,174 RSU shares were sold to cover taxes and 814 shares were sold on the open market. These amounts relate to RSUs described in the filing and occurred while establishing Williams’ reported post-transaction holdings.

What role does Sarah Joanne Williams hold at AN2 Therapeutics (ANTX)?

Sarah Joanne Williams is identified as an officer of AN2 Therapeutics, serving as the company’s Principal Accounting Officer. The Form 3 reflects her equity holdings in that capacity, including common stock, RSUs, and stock options subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 06:08 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Williams Sarah Joanne

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/26/2026

3. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	18,800(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	02/25/2035	Common Stock	21,875	$1.13	D
Stock Option (right to buy)	(3)	06/16/2034	Common Stock	23,700	$2.07	D

Explanation of Responses:

1. Includes the balance of (a) 10,938 RSUs which vest as follows: 1/4th of the RSUs vest in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (b) 11,850 RSUs which vest as follows: 1/16th of the RSUs vest in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. A total of 3,174 shares from the aggregate number of the RSUs issued under (a) and (b) above were sold to cover taxes and a total of 814 shares were sold on the open market.

2. The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and become exercisable (rounded down to the nearest whole number of shares) monthly over four years from January 1, 2025 until fully vested and exercisable on January 1, 2029, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

3. The shares subject to the option are exercisable and vest as follows: 1/4th of the shares vest and become exercisable (rounded down to the nearest whole number of shares) on the first anniversary of May 28, 2024, and 1/48th of the shares vest and become exercisable monthly (rounded down to the nearest whole number of shares) over the following three years until fully vested and exercisable on May 28, 2028, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

	/s/ Sarah Joanne Williams	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.